The Reagan-Udall Foundation for the FDA hosted a public meeting titled “Advancing Treatments for Post-Traumatic Stress Disorder,” in alignment with FDA’s ongoing efforts to better understand the medical needs surrounding PTSD with a goal of facilitating treatment development. This report summarizes the event that included a panel discussion with federal partners exploring efforts to accelerate treatment development for PTSD, including the potential role for psychedelic drugs.

Download Publication
Advancing Treatments for PTSD